Skip to main content
The Egyptian Journal of Bronchology
Download PDF
  • Original article
  • Open access
  • Published:

Forced vital capacity as a primary clinical outcome measure of bronchodilator reversibility in chronic obstructive pulmonary disease

Egyptian Journal of Bronchology volume 13, pages 29–34 (2019)Cite this article

Abstract

Background

Spirometry is the most reproducible and objective measurement of airflow limitation. The effectiveness of inhaled bronchodilator in individual patients with chronic obstructive pulmonary disease (COPD) is assessed by comparing measurements from pulmonary function tests made before and after administration. Generally forced expiratory volume in one second (FEV1) is the marker used with the global initiative for COPD (Global Initiative for Chronic Obstructive Lung Disease) guidelines. An increase in FEV1 that is both greater than 0.2 l and 12% above the prebronchodilator FEV1 value is considered significant.

The aim of this study is to assess forced vital capacity (FVC) as a clinical outcome measure of bronchodilator reversibility in patients with COPD.

Patients and methods

This was a prospective study conducted on 163 patients with COPD at Suez Chest Hospital during the period from first of October 2016 till the end of March 2017. Patients were diagnosed based on clinical and spirometric criteria, and then reversibility test was done using inhaled short-acting B2-agonist. All patients were subjected to COPD Assessment Test questionnaire.

Results

Overall, 14.11% of patients had significant increase in FEV1, whereas 54.6% of patients had significant increase in FVC after bronchodilator inhalation. There was a highly significant positive correlation in FEV1 and FVC value before and after bronchodilator inhalation, and there was a highly significant direct correlation between ΔFEV1 and ΔFVC. There was a statistically significant relation between age and COPD Assessment Test score and ΔFVC.

Conclusion

ΔFEV1 underestimates the true effect of bronchodilator as airway obstruction increases. The addition of ΔFVC to the evaluation will help physicians to better interpret airways reversibility tests, particularly in more severe patients, without adding spirometric maneuvers or measurements. Patients with COPD, even if nonresponders in terms of FEV1, may benefit from bronchodilators because they can breathe at a lower lung volume owing to reduced air-trapping, notwithstanding the fact that they are still flow limited. ΔFVC correlates better than ΔFEV1with the degree of airway obstruction and the clinical status of the patients.

References

  1. Global Strategy For The Diagnosis, Management, And Prevention Of Chronic Obstructive Pulmonary Disease (2018 Report). p. 25. https://goldcopd.org/wp-content/uploads/2017/11/GOLD-2018-v6.0-FINAL-revised-20-Nov_WMS.pdf

  2. Jones PW. Health status and the spiral of decline. COPD 2009; 6: 59–65.

    Article  Google Scholar 

  3. Rabe KF, Hurd S, Anzueto A, Barnes PJ, Buist SA, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007; 176: 532–555.

    Article  Google Scholar 

  4. COPD Assessment Test. The COPD Assessment Test was developed by a multi-disciplinary group of international experts in COPD supported by GSK. COPD Assessment Test and the CAT logo is a trademark of the GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. Available at: http://www.catestonline.org/english/index_Arabic.htm.

  5. Steenbruggen I, Mitchell S, Severin T, Palange P, Cooper BG, Spirometry HERMES Task Force. Harmonising spirometry education with HERMES: training a new generation of qualified spirometry practitioners across Europe. Eur Respir J 2011; 37: 479–481.

    Article  CAS  Google Scholar 

  6. Jarenbäck L, Eriksson G, Peterson S, Ankerst J, Bjermer L, Tufvesson E. Bronchodilator response of advanced lung function parameters depending on COPD severity. Int J Chron Obstruct Pulmon Dis 2016; 11: 2939–2950.

    Article  Google Scholar 

  7. Falco J, Martinb V, Marozzi L, Solís Aramayo MA, Hernández M, Sobrino E, et al. Volume response to a bronchodilator in patients with COPD. RAMR 2016; 2: 144–149.

    Google Scholar 

  8. Ben Saad H, Tabka Z, Zbidi A, Hayot M. The forgotten message from GOLD: FVC is a primary clinical outcome measure of bronchodilator reversibility in COPD. Pulm Pharmacol Ther 2008; 21: 767–773.

    Article  Google Scholar 

  9. Omata M, Wakabayashi R, Kudoh S, Kida K. Correlation between bronchodilator responsiveness and quality of life in chronic obstructive pulmonary disease. Allergol Int 2007; 56: 15–22.

    Article  Google Scholar 

  10. Schermer T, Heijdrab Y, Zadela S, van den Bemta L, Winterc LB, Dekhuijzenb R, et al. Flow and volume responses after routine salbutamol reversibility testing in mild to very severe COPD. Respir Med 2007; 101: 1355–1362.

    Article  Google Scholar 

  11. Quanjer PH, Ruppel GL, Langhammer A, Krishna A, Mertens F, Johannessen A, et al. Bronchodilator response in FVC is larger and more relevant than FEV1 in severe airflow obstruction. Chest 2017; 151: 1088–1098.

    Article  Google Scholar 

  12. Jarenbäck L, Eriksson G, Tufvesson E, Peterson S, Ankerst J, Bjermer L, et al. Bronchodilator response of lung function parameters depending on COPD severity. Int J Chron Obstruct Pulmon Dis 2016; 11: 2939–2950.

    Article  Google Scholar 

  13. Pisi R, Chetta A, Aiello M, Zanini A, Tzani P, Nicolini G, et al. Small airway dysfunction and flow and volume bronchodilator responsiveness in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 1191–1197.

    CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Chest Diseases, Faculty of Medicine, Ain Shams University, 15 Abdel Halim Nwera Street, New Nozha, 11843, Cairo, Egypt

    Magdy Mohamed Khalil & Eman Badawy AbdelFattah MD

  2. Department of Chest Diseases, Suez Chest Hospital, Suez, Egypt

    Yasmin Yousif Mostafa

Authors
  1. Magdy Mohamed Khalil
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Eman Badawy AbdelFattah MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Yasmin Yousif Mostafa
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Eman Badawy AbdelFattah MD.

Additional information

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

Rights and permissions

This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Khalil, M.M., AbdelFattah, E.B. & Mostafa, Y.Y. Forced vital capacity as a primary clinical outcome measure of bronchodilator reversibility in chronic obstructive pulmonary disease. Egypt J Bronchol 13, 29–34 (2019). https://doi.org/10.4103/ejb.ejb_31_18

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.4103/ejb.ejb_31_18

Keywords